Clinical Trials Directory

Trials / Unknown

UnknownNCT03900390

The Study of Potency of Cross-preconditioning to Prevent Ischemic-reperfusion Injury for Heart Transplantation Recipient

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
80 (estimated)
Sponsor
Mengya Liang · Academic / Other
Sex
All
Age
Healthy volunteers
Not accepted

Summary

In recent years, a large number of studies confirmed the protective effect of ischemic preconditioning on myocardium against ischemia/reperfusion injury, but the clinical data of the effectiveness of ischemic preconditioning in heart transplantation is still missing. Inspired by the promising data of ischemic preconditioning from the previous reports, the investigators firstly introduce a novel method of cross ischemic preconditioning technique to prevent ischemia/reperfusion injury to heart transplant recipients. This study will evaluate whether this cross-preconditioning technique would attenuate ischemia/ reperfusion injury to the heart transplant recipients, reduce Intensive Care Unit(ICU) and total hospitalization stays and the incidence of cardiovascular adverse events and improve the long-term survival outcomes.

Detailed description

Patients receiving heart transplantation are randomly assigned into the cross ischemic preconditioning (CICP) intervention group and the control group. (the Statistical Analysis System (SAS) software was used to generate a random number table and randomly divided into two groups). After the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions. The recipients in the control group are to undergo routine cardiopulmonary bypass procedure of heart transplantation.

Conditions

Interventions

TypeNameDescription
PROCEDUREcross-preconditioningAfter the establishment of the cardiopulmonary bypass, the ascending aorta of the CICP group will be crossclamped 2 minutes, separated by a 3-minute rest interval, and repeated successively on 2 occasions.

Timeline

Start date
2017-07-07
Primary completion
2022-07-07
Completion
2023-07-07
First posted
2019-04-03
Last updated
2019-04-03

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03900390. Inclusion in this directory is not an endorsement.